Genetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug Combinations

English version České info

The evolution of drug resistance in fungal pathogens compromises the efficacy of the limited number of antifungal drugs. Drug combinations have emerged as a powerful strategy to enhance antifungal efficacy and abrogate drug resistance, but the impact on the evolution of drug resistance remains largely unexplored. Targeting the molecular chaperone Hsp90 or its downstream effector, the protein phosphatase calcineurin, abrogates resistance to the most widely deployed antifungals, the azoles, which inhibit ergosterol biosynthesis. Here, we evolved experimental populations of the model yeast Saccharomyces cerevisiae and the leading human fungal pathogen Candida albicans with azole and an inhibitor of Hsp90, geldanamycin, or calcineurin, FK506. To recapitulate a clinical context where Hsp90 or calcineurin inhibitors could be utilized in combination with azoles to render resistant pathogens responsive to treatment, the evolution experiment was initiated with strains that are resistant to azoles in a manner that depends on Hsp90 and calcineurin. Of the 290 lineages initiated, most went extinct, yet 14 evolved resistance to the drug combination. Drug target mutations that conferred resistance to geldanamycin or FK506 were identified and validated in five evolved lineages. Whole-genome sequencing identified mutations in a gene encoding a transcriptional activator of drug efflux pumps, PDR1, and a gene encoding a transcriptional repressor of ergosterol biosynthesis genes, MOT3, that transformed azole resistance of two lineages from dependent on calcineurin to independent of this regulator. Resistance also arose by mutation that truncated the catalytic subunit of calcineurin, and by mutation in LCB1, encoding a sphingolipid biosynthetic enzyme. Genome analysis revealed extensive aneuploidy in four of the C. albicans lineages. Thus, we identify molecular determinants of the transition of azole resistance from calcineurin dependence to independence and establish multiple mechanisms by which resistance to drug combinations evolves, providing a foundation for predicting and preventing the evolution of drug resistance.

Vyšlo v časopise: Genetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug Combinations. PLoS Genet 9(4): e32767. doi:10.1371/journal.pgen.1003390
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003390

Souhrn

Zdroje

1. BushK, CourvalinP, DantasG, DaviesJ, EisensteinB, et al. (2011) Tackling antibiotic resistance. Nat Rev Microbiol 9: 894–896.

2. ChopraI (2012) The 2012 Garrod Lecture: Discovery of antibacterial drugs in the 21st century. J Antimicrob Chemother 68(3): 496–505 doi:10.1093/jac/dks436.

3. PalumbiSR (2001) Humans as the world's greatest evolutionary force. Science 293: 1786–1790.

4. ShapiroRS, RobbinsN, CowenLE (2011) Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75: 213–267.

5. CowenLE (2008) The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 6: 187–198.

6. BrownGD, DenningDW, LevitzSM (2012) Tackling human fungal infections. Science 336: 647.

7. PfallerMA, DiekemaDJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1–53.

8. TorellaJP, ChaitR, KishonyR (2010) Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol 6: e1000796 doi:10.1371/journal.pcbi.1000796.

9. zur WieschPA, KouyosR, EngelstadterJ, RegoesRR, BonhoefferS (2011) Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 11: 236–247.

10. HoggRS, HeathKV, YipB, CraibKJ, O'ShaughnessyMV, et al. (1998) Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279: 450–454.

11. PalellaFJJr, DelaneyKM, MoormanAC, LovelessMO, FuhrerJ, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–860.

12. NakagawaF, LodwickRK, SmithCJ, SmithR, CambianoV, et al. (2012) Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 26: 335–343.

13. WHO (2011) World Malaria Report 2011. World Health Organization. Geneva, Switzerland: WHO Press. 79 p. Available: http://www.who.int/malaria/world_malaria_report_2011/en/.

14. WHO (2012) Global Tuberculosis Report 2012. World Health Organization. Geneva, Switzerland: WHO Press. 91 p. Available: http://www.who.int/tb/publications/global_report/en/.

15. SteinbachWJ, ReedyJL, CramerRAJr, PerfectJR, HeitmanJ (2007) Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5: 418–430.

16. CowenLE, LindquistS (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185–2189.

17. TaipaleM, JaroszDF, LindquistS (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515–528.

18. CruzMC, GoldsteinAL, BlankenshipJR, Del PoetaM, DavisD, et al. (2002) Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 21: 546–559.

19. ImaiJ, YaharaI (2000) Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin. Mol Cell Biol 20: 9262–9270.

20. CowenLE, CarpenterAE, MatangkasombutO, FinkGR, LindquistS (2006) Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell 5: 2184–2188.

21. SinghSD, RobbinsN, ZaasAK, SchellWA, PerfectJR, et al. (2009) Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 5: e1000532 doi:10.1371/journal.ppat.1000532.

22. CowenLE, SinghSD, KohlerJR, CollinsC, ZaasAK, et al. (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 106: 2818–2823.

23. RobbinsN, UppuluriP, NettJ, RajendranR, RamageG, et al. (2011) Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 7: e1002257 doi:10.1371/journal.ppat.1002257.

24. UppuluriP, NettJ, HeitmanJ, AndesD (2008) Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52: 1127–1132.

25. SanglardD (2002) Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol 5: 379–385.

26. AndersonJB (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3: 547–556.

27. WhiteTC, MarrKA, BowdenRA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: 382–402.

28. BalziE, WangM, LetermeS, Van DyckL, GoffeauA (1994) PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1. J Biol Chem 269: 2206–2214.

29. FavreB, DidmonM, RyderNS (1999) Multiple amino acid substitutions in lanosterol 14alpha-demethylase contribute to azole resistance in Candida albicans. Microbiology 145(Pt 10): 2715–2725.

30. AndersonJB, SirjusinghC, ParsonsAB, BooneC, WickensC, et al. (2003) Mode of selection and experimental evolution of antifungal drug resistance in Saccharomyces cerevisiae. Genetics 163: 1287–1298.

31. MarchettiO, MoreillonP, GlauserMP, BilleJ, SanglardD (2000) Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 44: 2373–2381.

32. PfallerMA, DiekemaDJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133–163.

33. HornDL, NeofytosD, AnaissieEJ, FishmanJA, SteinbachWJ, et al. (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48: 1695–1703.

34. MarrKA (2010) Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol 22: 138–142.

35. PfallerMA (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125: S3–13.

36. BermanJ, SudberyPE (2002) Candida albicans: a molecular revolution built on lessons from budding yeast. Nat Rev Genet 3: 918–930.

37. CowenLE, SteinbachWJ (2008) Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 7: 747–764.

38. OnyewuC, BlankenshipJR, Del PoetaM, HeitmanJ (2003) Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 47: 956–964.

39. HemenwayCS, HeitmanJ (1999) Calcineurin. Structure, function, and inhibition. Cell Biochem Biophys 30: 115–151.

40. EtzkornFA, ChangZY, StolzLA, WalshCT (1994) Cyclophilin residues that affect noncompetitive inhibition of the protein serine phosphatase activity of calcineurin by the cyclophilin.cyclosporin A complex. Biochemistry 33: 2380–2388.

41. KissingerCR, PargeHE, KnightonDR, LewisCT, PelletierLA, et al. (1995) Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378: 641–644.

42. SchulteTW, AkinagaS, SogaS, SullivanW, StensgardB, et al. (1998) Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 3: 100–108.

43. StebbinsCE, RussoAA, SchneiderC, RosenN, HartlFU, et al. (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89: 239–250.

44. BorkovichKA, FarrellyFW, FinkelsteinDB, TaulienJ, LindquistS (1989) Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol 9: 3919–3930.

45. MinamiY, KimuraY, KawasakiH, SuzukiK, YaharaI (1994) The carboxy-terminal region of mammalian HSP90 is required for its dimerization and function in vivo. Mol Cell Biol 14: 1459–1464.

46. CyertMS, KunisawaR, KaimD, ThornerJ (1991) Yeast has homologs (CNA1 and CNA2 gene products) of mammalian calcineurin, a calmodulin-regulated phosphoprotein phosphatase. Proc Natl Acad Sci U S A 88: 7376–7380.

47. HongayC, JiaN, BardM, WinstonF (2002) Mot3 is a transcriptional repressor of ergosterol biosynthetic genes and is required for normal vacuolar function in Saccharomyces cerevisiae. EMBO J 21: 4114–4124.

48. KolaczkowskaA, GoffeauA (1999) Regulation of pleiotropic drug resistance in yeast. Drug Resist Updat 2: 403–414.

49. HendrychT, KodedovaM, SiglerK, GaskovaD (2009) Characterization of the kinetics and mechanisms of inhibition of drugs interacting with the S. cerevisiae multidrug resistance pumps Pdr5p and Snq2p. Biochim Biophys Acta 1788: 717–723.

50. CowenLE, SanglardD, CalabreseD, SirjusinghC, AndersonJB, et al. (2000) Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 182: 1515–1522.

51. SanglardD, IscherF, MarchettiO, EntenzaJ, BilleJ (2003) Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 48: 959–976.

52. BuedeR, Rinker-SchafferC, PintoWJ, LesterRL, DicksonRC (1991) Cloning and characterization of LCB1, a Saccharomyces gene required for biosynthesis of the long-chain base component of sphingolipids. J Bacteriol 173: 4325–4332.

53. DicksonRC, LesterRL (2002) Sphingolipid functions in Saccharomyces cerevisiae. Biochim Biophys Acta 1583: 13–25.

54. SpitzerM, GriffithsE, BlakelyKM, WildenhainJ, EjimL, et al. (2011) Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol 7: 499.

55. ChenJK, LaneWS, SchreiberSL (1999) The identification of myriocin-binding proteins. Chem Biol 6: 221–235.

56. AndersonJB, FuntJ, ThompsonDA, PrabhuS, SochaA, et al. (2010) Determinants of divergent adaptation and Dobzhansky-Muller interaction in experimental yeast populations. Curr Biol 20: 1383–1388.

57. DettmanJR, RodrigueN, MelnykAH, WongA, BaileySF, et al. (2012) Evolutionary insight from whole-genome sequencing of experimentally evolved microbes. Mol Ecol 21: 2058–2077.

58. BlazquezJ (2003) Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin Infect Dis 37: 1201–1209.

59. SelmeckiAM, DulmageK, CowenLE, AndersonJB, BermanJ (2009) Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet 5: e1000705 doi:10.1371/journal.pgen.1000705.

60. WhiteTC (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41: 1482–1487.

61. ChenB, ZhongD, MonteiroA (2006) Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms. BMC Genomics 7: 156.

62. NeckersL, WorkmanP (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64–76.

63. TrepelJ, MollapourM, GiacconeG, NeckersL (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537–549.

64. WhitesellL, LindquistSL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761–772.

65. MillsonSH, ProdromouC, PiperPW (2010) A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta. Biochem Pharmacol 79: 1581–1588.

66. ProdromouC, NuttallJM, MillsonSH, RoeSM, SimTS, et al. (2009) Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chem Biol 4: 289–297.

67. EricsonE, HoonS, St OngeRP, GiaeverG, NislowC (2010) Exploring gene function and drug action using chemogenomic dosage assays. Methods Enzymol 470: 233–255.

68. HeitmanJ, MovvaNR, HiestandPC, HallMN (1991) FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 88: 1948–1952.

69. CardenasME, MuirRS, BreuderT, HeitmanJ (1995) Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. EMBO J 14: 2772–2783.

70. GaaliS, GopalakrishnanR, WangY, KozanyC, HauschF (2011) The chemical biology of immunophilin ligands. Curr Med Chem 18: 5355–5379.

71. PayaCV (1993) Fungal infections in solid-organ transplantation. Clin Infect Dis 16: 677–688.

72. BlankenshipJR, SinghN, AlexanderBD, HeitmanJ (2005) Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. J Clin Microbiol 43: 464–467.

73. ReedyJL, HusainS, IsonM, PruettTL, SinghN, et al. (2006) Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. Antimicrob Agents Chemother 50: 1573–1577.

74. LaFayetteSL, CollinsC, ZaasAK, SchellWA, Betancourt-QuirozM, et al. (2010) PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog 6: e1001069 doi:10.1371/journal.ppat.1001069.

75. AlbertiS, HalfmannR, KingO, KapilaA, LindquistS (2009) A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 137: 146–158.

76. AndersonJB, RickerN, SirjusinghC (2006) Antagonism between two mechanisms of antifungal drug resistance. Eukaryot Cell 5: 1243–1251.

77. SelmeckiA, ForcheA, BermanJ (2006) Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313: 367–370.

78. SelmeckiA, Gerami-NejadM, PaulsonC, ForcheA, BermanJ (2008) An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 68: 624–641.

79. SasseC, DunkelN, SchaferT, SchneiderS, DierolfF, et al. (2012) The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. Mol Microbiol 86: 539–556.

80. CowenLE, KohnLM, AndersonJB (2001) Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 183: 2971–2978.

81. SelmeckiA, ForcheA, BermanJ (2010) Genomic plasticity of the human fungal pathogen Candida albicans. Eukaryot Cell 9: 991–1008.

82. DolginE, MotlukA (2011) Heat shock and awe. Nat Med 17: 646–649.

83. LuoW, SunW, TaldoneT, RodinaA, ChiosisG (2010) Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener 5: 24.

84. YehPJ, HegrenessMJ, AidenAP, KishonyR (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7: 460–466.

85. ChaitR, CraneyA, KishonyR (2007) Antibiotic interactions that select against resistance. Nature 446: 668–671.

86. HegrenessM, ShoreshN, DamianD, HartlD, KishonyR (2008) Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A 105: 13977–13981.

87. MichelJB, YehPJ, ChaitR, MoelleringRCJr, KishonyR (2008) Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci U S A 105: 14918–14923.

88. WahlLM, GerrishPJ (2001) The probability that beneficial mutations are lost in populations with periodic bottlenecks. Evolution 55: 2606–2610.

89. SmithAM, HeislerLE, St OngeRP, Farias-HessonE, WallaceIM, et al. (2010) Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples. Nucleic acids research 38: e142.

90. EngelSR, BalakrishnanR, BinkleyG, ChristieKR, CostanzoMC, et al. (2010) Saccharomyces Genome Database provides mutant phenotype data. Nucleic acids research 38: D433–436.

91. SkrzypekMS, ArnaudMB, CostanzoMC, InglisDO, ShahP, et al. (2010) New tools at the Candida Genome Database: biochemical pathways and full-text literature search. Nucleic acids research 38: D428–432.

92. JonesT, FederspielNA, ChibanaH, DunganJ, KalmanS, et al. (2004) The diploid genome sequence of Candida albicans. Proceedings of the National Academy of Sciences of the United States of America 101: 7329–7334.

93. van het HoogM, RastTJ, MartchenkoM, GrindleS, DignardD, et al. (2007) Assembly of the Candida albicans genome into sixteen supercontigs aligned on the eight chromosomes. Genome biology 8: R52.

94. LangmeadB, TrapnellC, PopM, SalzbergSL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome biology 10: R25.

95. LiH, RuanJ, DurbinR (2008) Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome research 18: 1851–1858.

96. LiR, LiY, KristiansenK, WangJ (2008) SOAP: short oligonucleotide alignment program. Bioinformatics 24: 713–714.

97. LiH, DurbinR (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754–1760.

98. LangmeadB, SalzbergSL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9: 357–359.

99. LiH, HomerN (2010) A survey of sequence alignment algorithms for next-generation sequencing. Brief Bioinform 11: 473–483.

100. LiH, HandsakerB, WysokerA, FennellT, RuanJ, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078–2079.

101. FiumeM, WilliamsV, BrookA, BrudnoM (2010) Savant: genome browser for high-throughput sequencing data. Bioinformatics 26: 1938–1944.

102. McKennaA, HannaM, BanksE, SivachenkoA, CibulskisK, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research 20: 1297–1303.

103. DePristoMA, BanksE, PoplinR, GarimellaKV, MaguireJR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43: 491–498.

104. RothA, DingJ, MorinR, CrisanA, HaG, et al. (2012) JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data. Bioinformatics 28: 907–913.

105. LitiG, CarterDM, MosesAM, WarringerJ, PartsL, et al. (2009) Population genomics of domestic and wild yeasts. Nature 458: 337–341.

106. XieC, TammiMT (2009) CNV-seq, a new method to detect copy number variation using high-throughput sequencing. BMC bioinformatics 10: 80.